Compare

Puretech Health/£PRTC

1D1W1M3M6MYTD1Y5YMAX

About Puretech Health

PureTech Health, trading under the ticker PRTC, is a biotechnology company focused on discovering, developing, and commercializing highly differentiated medicines for devastating diseases. Operating within the healthcare sector, the company leverages its deep expertise in the understanding of disease physiology to advance a pipeline of novel therapies addressing serious medical conditions. Founded in 2015, PureTech Health engages in groundbreaking translational research that bridges the gap between innovative biological insights and potential impactful therapies.
Ticker
£PRTC
Sector
Health
Primary listing
LSE
Employees
90
Headquarters
Boston, United States
Website
www.puretechhealth.com

Puretech Health Metrics

BasicAdvanced
£280M
195.12
£0.01
0.78
-

What the Analysts think about Puretech Health

Analyst ratings (Buy, Hold, Sell) for Puretech Health stock.
Analyst projections of the future price of Puretech Health stock.

Bulls say / Bears say

Celea secured $180 million from external investors and launched a Phase 3 trial of deupirfenidone, while PureTech retains equity and royalty-based economics. This moves a costly programme forward without leaving PureTech to fund the whole trial itself. (PureTech Health)
PureTech’s 31.2% holding in Seaport was valued at about $360 million after Seaport’s Nasdaq listing, alongside retained royalty and milestone rights. That gives PureTech a sizeable listed asset and potential further value from Seaport’s pipeline. (PureTech Health)
LYT-200 produced responses in a Phase 1b study of heavily pretreated blood-cancer patients, and the FDA has supported moving it into a Phase 2 trial for high-risk MDS; it also granted Fast Track status. This gives Gallop a clearer next-stage development path, though the evidence is still early. (Business Wire, BioSpace)
The encouraging LYT-200 MDS response data come from just 11 efficacy-evaluable patients in an early-stage study, and median overall survival was not mature. A larger, controlled trial will need to confirm whether the result is reliable and clinically meaningful. (Business Wire)
Gallop expects to secure external funding in the first half of 2027 to support LYT-200’s next trial. If that capital is delayed or unavailable on acceptable terms, development could slow or put more pressure on PureTech’s own resources. (BioSpace, PureTech Health)
PureTech used $44.4 million in operating cash in the first half of 2026, while cash and short-term investments fell to $220 million from $277 million at year-end. The company still expects to have runway through 2028, but that forecast assumes it may deploy a further $70 million into Celea. (PureTech Health)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.

Puretech Health Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Puretech Health Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.